Effect of Cinacalcet Combined With Sevelamer Hydrochloride on the Incidence of Urolithiasis in Maintenance Hemodialysis Patients With Diabetic Kidney Disease

<p style="text-align:justify;"> Background: Diabetic kidney disease is a major cause of end-stage renal disease, and patients undergoing maintenance haemodialysis are at high risk of urolithiasis due to metabolic disorders. Sevelamer hydrochloride alone has limited efficacy in preventing urolithiasis, whilst the combined effect of cinacalcet and sevelamer hydrochloride lacks sufficient evidence-based support. <p style="text-align:justify;"> Methods: The clinical data of 120 patients in our hospital from January 2020 to December 2023 were retrospectively collected. The patients were divided into a combined group (n = 60, cinacalcet + sevelamer hydrochloride) and a control group (n = 60, sevelamer hydrochloride alone), and their baseline data were collected. The incidence, recurrence rate, maximum stone diameter, urinary pH, 24-hour urine volume and urinary calcium were compared at 6 and 12 months of treatment. <p style="text-align:justify;"> Results: No statistically significant differences in baseline data were found (p > 0.05), indicating comparability. At 6 and 12 months, urolithiasis incidence (11.67%, 18.33%) and recurrence rate (11.11%, 33.33%) in the combined group were significantly lower than those in the control group (30.00%, 50.00% and 45.45%, 72.73%, respectively; p < 0.05). The combined group also exhibited higher urine pH and 24-hour urine volume, lower urinary calcium levels and smaller maximum stone diameter compared with the control group (p < 0.05). <div style="text-align:justify;"> Conclusions: Cinacalcet combined with sevelamer hydrochloride can effectively reduce the incidence and recurrence rate of urolithiasis, inhibit stone enlargement and regulate urine pH in patients with diabetic kidney disease undergoing maintenance haemodialysis. It has a positive effect on the prevention and improvement of urolithiasis and can be considered as one of the preferred clinical treatment options for these patients. </div> <div> <br /> </div>

Publication Details

Journal
Archivos Españoles de Urología
Published
2026-01-01
DOI
https://doi.org/10.56434/j.arch.esp.urol.20267902.39
Primary Topic
Parathyroid Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effect of Cinacalcet Combined With Sevelamer Hydrochloride on the Incidence of Urolithiasis in Maintenance Hemodialysis Patients With Diabetic Kidney Disease

Archivos Españoles de Urología
Parathyroid Disorders and Treatments
article

Effect of Cinacalcet Combined With Sevelamer Hydrochloride on the Incidence of Urolithiasis in Maintenance Hemodialysis Patients With Diabetic Kidney Disease

article en

Abstract

<p style="text-align:justify;"> Background: Diabetic kidney disease is a major cause of end-stage renal disease, and patients undergoing maintenance haemodialysis are at high risk of urolithiasis due to metabolic disorders. Sevelamer hydrochloride alone has limited efficacy in preventing urolithiasis, whilst the combined effect of cinacalcet and sevelamer hydrochloride lacks sufficient evidence-based support. <p style="text-align:justify;"> Methods: The clinical data of 120 patients in our hospital from January 2020 to December 2023 were retrospectively collected. The patients were divided into a combined group (n = 60, cinacalcet + sevelamer hydrochloride) and a control group (n = 60, sevelamer hydrochloride alone), and their baseline data were collected. The incidence, recurrence rate, maximum stone diameter, urinary pH, 24-hour urine volume and urinary calcium were compared at 6 and 12 months of treatment. <p style="text-align:justify;"> Results: No statistically significant differences in baseline data were found (p > 0.05), indicating comparability. At 6 and 12 months, urolithiasis incidence (11.67%, 18.33%) and recurrence rate (11.11%, 33.33%) in the combined group were significantly lower than those in the control group (30.00%, 50.00% and 45.45%, 72.73%, respectively; p < 0.05). The combined group also exhibited higher urine pH and 24-hour urine volume, lower urinary calcium levels and smaller maximum stone diameter compared with the control group (p < 0.05). <div style="text-align:justify;"> Conclusions: Cinacalcet combined with sevelamer hydrochloride can effectively reduce the incidence and recurrence rate of urolithiasis, inhibit stone enlargement and regulate urine pH in patients with diabetic kidney disease undergoing maintenance haemodialysis. It has a positive effect on the prevention and improvement of urolithiasis and can be considered as one of the preferred clinical treatment options for these patients. </div> <div> <br /> </div>

Archivos Españoles de UrologíaVol. 79(2)
Good health and well-being
Openalex Percentile: Top 3%
Parathyroid Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.